Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...

Blue Bird Corporation remains a “Strong Buy” due to its solid backlog, strong funding, and undervaluation, despite recent ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Blue Bird Corporation (NASDAQ:BLBD), a leading manufacturer of school buses, has been making significant strides in the electric vehicle (EV) market while improving its operational efficiency.

In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...

Blue Bird beat analysts’ revenue expectations by 5.3% last quarter, reporting revenues of $350.2 million, up 15.6% year on year. It was a very strong quarter for the company, with a solid beat ...

Blue Bird tops Q1 earnings estimates on strong demand and a robust backlog. But will policy risks derail its momentum? Check ...

Blue Bird Corporation (NASDAQ ... supported by strong profitability metrics and solid balance sheet management. This comprehensive analysis examines the company's recent performance, strategic ...

They downed the Yankees yesterday. Today it’s the Red Sox’ turn. Yariel Rodriguez will start for the Jays, while Garrett Crochet goes for Boston. It’s both of their first appearance of the season.